News Release
 

April 22, 2010

CONTACT: Karen Kreeger
215-349-5658
karen.kreeger@uphs.upenn.edu

Penn Medicine - University of Pennsylvania School of Medicine and University of Pennsylvania Health System


This release is available online at
http://www.uphs.upenn.edu/news/News_Releases/2010/04/genetic-basis-of-cancer/

Invitation to Cover: Genetic Basis of Cancer

A Symposium in Honor of Penn’s Peter C. Nowell, Recipient of the 2010 Benjamin Franklin Medal in Life Science

WHAT:

The relationship between chromosome alterations and cancer had been debated for more than one hundred years. The first direct link between chromosomal abnormalities to any malignancy came with the discovery of the Philadelphia chromosome in 1960 by Peter Nowell at the School of Medicine and the late David Hungerford from the Fox Chase Cancer Center’s Institute for Cancer Research. Understanding abnormalities in the replication of the chromosome led to the eventual development of the genetically targeted cancer drug Gleevec in 2001. This symposium celebrates the 50th Anniversary of the discovery of the Philadelphia chromosome and brings us up to date on the genetic basis of cancer, addressing the role of tyrosine kinase enzymes, microRNAs, and immune cells.

 

WHEN:

Friday, April 30, 2010
10:00am

 

WHERE:

Stemmler Hall – Dunlop Auditorium
3450 Hamilton Walk, Philadelphia, PA 19104

http://www.pennmedicine.org/hup/vi_files/maps-campus.html

 

SPEAKERS:

  • Mark Greene, MD, PhD, FRCP, University of Pennsylvania School of Medicine
    Kinases and Transformation
  • Carlo Croce, MD, Ohio State University Medical Center
    Causes and Consequences of MicroRNA Dysregulation in Cancer
  • Gary Koretzky, MD, PhD, University of Pennsylvania School of Medicine
    Signals Regulating Immune Cell Development and Activation
  • Mark Lemmon, PhD, University of Pennsylvania School of Medicine
    New Lessons in Understanding Regulation of the EGF Receptor Family
  • Joseph Schlessinger, PhD, Yale University School of Medicine
    Cell Signaling by Receptor Tyrosine Kinases: From Basic Principles to Cancer Therapy

Free and open to the public. Please RSVP to Zoe Zampana, 215.615.6510; zampanaz@mail.med.upenn.edu

###

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2013 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2013, Penn Medicine provided $814 million to benefit our community.